Keyphrases
Synergistic Cytotoxicity
81%
Decitabine
81%
PARP Inhibitor (PARPi)
81%
Histone Deacetylase 1 (HDAC1)
81%
Engineered T-cell Receptor
40%
Chimeric Antigen Receptor T-cell Therapy
40%
Molecular Tumor Board
40%
Precision Oncology
40%
Adoptive Cell Therapy
40%
T Cell Exhaustion
40%
Advanced Cancer
40%
Pancreatic Cancer Cells
40%
T Cell Differentiation
40%
Novel Therapies
40%
Novel Therapeutics
40%
Breast Cancer Cells
40%
Therapeutic Combinations
40%
Ovarian Cancer Cells
40%
Histone Deacetylase Inhibitor (HDACi)
38%
T Cells
30%
Olaparib
28%
Vorinostat
28%
Panobinostat
28%
Talazoparib
28%
Molecular Alterations
23%
Allele-specific Expression
20%
Cytokine Release Syndrome
20%
Median Progression-free Survival
20%
Tumor Expression
20%
Matrix metalloproteinase-1 (MMP-1)
20%
MAGE-A4
20%
Disease Stabilization
20%
Adverse Events
20%
Therapeutic Program
20%
MXRA5
20%
MAGE-A
20%
Lymphodepletion
20%
Leukapheresis
20%
Cytopenia
20%
Atezolizumab
20%
Specific T Cells
20%
Cell Manufacturing
20%
Exon 6
20%
Overall Survival
20%
Patients with Advanced Cancer
20%
Effector Function
20%
Stable Disease
20%
T Cell Biology
20%
Interleukin-2
20%
HLA-A*02
20%
Medicine and Dentistry
Neoplasm
100%
Oncology
81%
Decitabine
81%
Histone Deacetylase
81%
Cancer Cell
81%
PARP Inhibitor
81%
Cytotoxicity
81%
T Cell
51%
Advanced Cancer
47%
Clinical Trial
46%
Chimeric Antigen Receptor T-Cell Immunotherapy
40%
Pancreas Cancer
40%
T Lymphocyte Receptor
40%
T Cell Differentiation
40%
Cell Therapy
40%
Breast Cancer
40%
Ovarian Cancer
40%
Histone Deacetylase Inhibitor
38%
Vorinostat
28%
Olaparib
28%
Panobinostat
28%
Talazoparib
28%
Diseases
27%
Infusion
23%
Cytotechnology
20%
Combination Drug
18%
Biological Marker
17%
DNA Repair
14%
DNA Damage
14%
Cell Line
14%
Atezolizumab
13%
Progression Free Survival
13%
Interstitial Collagenase
13%
Interleukin 2
13%
Overall Survival
13%
Exon
13%
Cytopenia
13%
Leukapheresis
13%
Adverse Event
13%
HLA-A
13%
Allele
13%
Cytokine Release Syndrome
13%
CD8 Antigen
13%
Immunity
11%
Next Generation Sequencing
11%
Pancreatic Cancer Cell Line
10%
BRCA2
10%
Infection
10%
Cancer Therapy
10%
Immunological Memory
10%
Pharmacology, Toxicology and Pharmaceutical Science
Decitabine
81%
Cytotoxicity
81%
Histone Deacetylase
81%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
81%
T Lymphocyte Receptor
40%
Diseases
40%
Pancreas Cancer
40%
Advanced Cancer
40%
Ovary Cancer
40%
Breast Cancer
40%
Histone Deacetylase Inhibitor
38%
Olaparib
28%
Vorinostat
28%
Panobinostat
28%
Talazoparib
28%
Neoplasm
25%
Combination Drug
23%
Cytokine Release Syndrome
20%
Interstitial Collagenase
20%
Interleukin 2
20%
CD8 Antigen
20%
Atezolizumab
20%
Cytopenia
20%
Adverse Event
20%
Progression Free Survival
20%
Overall Survival
20%
Malignant Neoplasm
9%
Caspase 3
9%
Histone
9%
Transcriptional Regulator ATRX
5%
Nucleoside
5%
Cytidine
5%
Adenosine Diphosphate
5%
ATM Protein
5%
BRCA1 Protein
5%
Synergism
5%
DNA Methyltransferase
5%